Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Gsk Plc ADR (GSK)

Gsk Plc ADR (GSK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 122,773,192
  • Shares Outstanding, K 2,038,406
  • Annual Sales, $ 40,095 M
  • Annual Income, $ 3,291 M
  • EBIT $ 9,914 M
  • EBITDA $ 13,174 M
  • 60-Month Beta 0.46
  • Price/Sales 2.80
  • Price/Cash Flow 8.51
  • Price/Book 5.73

Options Overview Details

View History
  • Implied Volatility 28.64% (-2.34%)
  • Historical Volatility 29.53%
  • IV Percentile 66%
  • IV Rank 27.15%
  • IV High 61.51% on 10/23/25
  • IV Low 16.39% on 12/08/25
  • Expected Move (DTE 5) 1.85 (3.08%)
  • Put/Call Vol Ratio 0.28
  • Today's Volume 4,081
  • Volume Avg (30-Day) 5,471
  • Put/Call OI Ratio 0.56
  • Today's Open Interest 104,187
  • Open Int (30-Day) 74,217
  • Expected Range 58.38 to 62.08

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 1.20
  • Number of Estimates 4
  • High Estimate 1.28
  • Low Estimate 1.13
  • Prior Year 1.13
  • Growth Rate Est. (year over year) +6.19%

Price Performance

See More
Period Period Low Period High Performance
1-Month
47.62 +26.48%
on 01/20/26
60.37 -0.23%
on 02/06/26
+9.67 (+19.13%)
since 01/06/26
3-Month
45.81 +31.49%
on 11/20/25
60.37 -0.23%
on 02/06/26
+13.13 (+27.88%)
since 11/06/25
52-Week
32.38 +86.01%
on 04/09/25
60.37 -0.23%
on 02/06/26
+23.85 (+65.56%)
since 02/06/25

Most Recent Stories

More News
RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc. - RAPT

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of RAPT Therapeutics ...

RAPT : 57.69 (+0.02%)
GSK : 60.23 (+1.79%)
RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc. - RAPT

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of RAPT Therapeutics ...

RAPT : 57.69 (+0.02%)
GSK : 60.23 (+1.79%)
GSK Awards $2M in COiMMUNITY Initiative Grants to Help Close Vaccination Gaps, Commits $3M for 2026

Sixteen organizations, awarded funding in 2025, are taking innovative, local approaches to boosting vaccination in communities across the US Grant recipients’ projects aim to modernize...

GSK.LN : 2,198.000 (+0.83%)
GSK : 60.23 (+1.79%)
GSK Announces Recipients of Linked by Lupus: Optimal Care Initiative Grants Nearing $1 Million

Grant funding awarded to support lupus-focused community programs across the United States

GSK.LN : 2,198.000 (+0.83%)
GSK : 60.23 (+1.79%)
Flu Season's Here—This Dividend-Payer Controls the Shot Market

With flu season in full swing, drugmakers are hoping for a short-term tailwind after a lackluster 2025. Sanofi could be the winning ticket.

JNJ : 239.99 (+0.93%)
LLY : 1,058.18 (+3.66%)
ABBV : 223.43 (+2.01%)
GSK : 60.23 (+1.79%)
CSLLY : 64.2200 (+1.92%)
PFE : 27.22 (+2.76%)
SNY : 47.83 (+0.72%)
Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma

Exdensur is the first and only ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype Approval based...

GSK.LN : 2,198.000 (+0.83%)
GSK : 60.23 (+1.79%)
Breakthrough ASH Data Drives Blood Cancer Market To $240B Valuation

Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – The 2025 American Society of Hematology meeting showcased pivotal advances in blood cancer treatment, with...

PTGX : 84.49 (+4.74%)
KPTI : 6.26 (+2.79%)
GTBP : 0.5389 (+8.54%)
GSK : 60.23 (+1.79%)
TAK : 17.89 (+0.51%)
U.S. and U.K. Reach Agreement in Principle on Pharmaceutical Pricing in New Economic Prosperity Deal

The United States and the United Kingdom have reached an agreement in principle on pharmaceutical pricing as part of the new U.S.–U.K. Economic Prosperity Deal, aimed at addressing long-standing pricing...

MRK : 121.93 (+1.82%)
PFE : 27.22 (+2.76%)
GSK : 60.23 (+1.79%)
Blenrep approved by US FDA for use in treatment of relapsed/refractory multiple myeloma

Significant unmet need for patients requires new and novel treatments 1 DREAMM-7 showed a 51% reduction in the risk of death and tripled median progression-free...

GSK.LN : 2,198.000 (+0.83%)
GSK : 60.23 (+1.79%)
PIVOT-PO Phase 3 Data Show Tebipenem HBr’s Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)

Data presented at IDWeek 2025 after study stopped early for efficacy Primary endpoint met, demonstrating non-inferiority of oral tebipenem HBr compared to intravenous treatment 1 Data will be...

SPRO : 2.42 (+5.22%)
GSK : 60.23 (+1.79%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 80%. The market is in extreme overbought territory. Beware of a trend reversal.

See More Share

Business Summary

GSK plc is a biopharma company. Its vaccine portfolio protects people from meningitis, shingles, flu, polio, measles and many more. GSK plc, formerly known as GLAXOSMITHKLINE, is based in Brentford, the United Kingdom.

See More

Key Turning Points

3rd Resistance Point 61.77
2nd Resistance Point 61.07
1st Resistance Point 60.65
Last Price 60.23
1st Support Level 59.53
2nd Support Level 58.83
3rd Support Level 58.41

See More

52-Week High 60.37
Last Price 60.23
Fibonacci 61.8% 49.68
Fibonacci 50% 46.38
Fibonacci 38.2% 43.07
52-Week Low 32.38

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar